Premium
Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of treatment options
Author(s) -
Worswick Scott,
Cotliar Jonathan
Publication year - 2011
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2011.01396.x
Subject(s) - toxic epidermal necrolysis , medicine , thalidomide , plasmapheresis , dermatology , cyclophosphamide , erythroderma , surgery , intensive care medicine , chemotherapy , immunology , antibody , multiple myeloma
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous reactions that are medication‐induced in most instances. While the clinical manifestations of SJS and TEN are well‐defined, the optimal treatment for these disorders is not. Case reports have shown benefit with the use of a variety of agents including tumor necrosis factor‐alpha inhibitors and cyclophosphamide, whereas thalidomide was associated with an increased mortality. Plasmapheresis and cyclosporine have also demonstrated efficacy anecdotally, albeit with an even smaller number of cases in the literature. Most of the reporting has focused on the use of systemic corticosteroids and intravenous immunoglobulin (IVIG) for these severe reactions. The majority of studies analyzing the use of IVIG in the treatment of SJS/TEN show a benefit, though more recent series cast doubt upon this conclusion. The results of these studies are summarized in this present review study.